Christopher Rowley – Harvard AIDS Initiative

August 10, 2016June 30, 2018

Aldatu Licenses Technology from Harvard

One Step Closer to Affordable HIV Drug–Resistance Test By Martha Henry Harvard recently entered into a licensing agreement with Aldatu Biosciences for exclusive use of the PANDAA technology. Using PANDAA, Aldatu, a biotech start-up based at LabCentral in Cambridge, is developing a rapid HIV drug-resistance test for patients failing first-line antiretroviral therapy (ART).

March 12, 2015January 5, 2016

On The Way To Market

We wanted to update you on Dr. Iain MacLeod, another young HAI researcher, who is building a biotech start-up around a rapid HIV drug-resistance test that he and Dr. Christopher Rowley developed in the Essex Lab.